Australia EpiTan Limited

Endpoint trial of Melanotan begins in Sydney

Published in Law and Health Weekly, July 16th, 2005

Australia EpiTan Limited (EPT, EPTNY) announced that the first volunteers have been recruited into the phase IIb study to evaluate the photoprotective effect of a sustained release dose of Melanotan in Sydney.

Ethics approval for this trial was announced on March 7, 2005.

The trial is designed to validate two primary endpoints for Melanotan for fair-skinned Caucasians who are the expected target patients for this therapy. The trial aims to establish a "protection" rating for Melanotan similar to that used in sunscreens.

The second primary endpoint is to determine the change in skin pigmentation from baseline to week 4, 8 and 12...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Law and Health Weekly

Source: Law and Health Weekly (2005-07-16)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry